Bio-Rad's Q3 saw the company book $653 million in revenue, which was very modestly (0.5%) higher on a year-over-year basis. Net income not according to generally accepted accounting principles (GAAP) ...

Bio-Rad Laboratories BIO recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ddPCR system, along with ...

View Bio-Rad Laboratories, Inc. Class A BIO stock quote prices, financial information, real-time forecasts, and company news from CNN.

Bio-Rad Laboratories, Inc. BIO is well-poised to grow in the upcoming quarters, courtesy of its strong traction in the QX600 Droplet Digital PCR (ddPCR) platform. Demand for its quality control and ...

May 17 (Reuters) - Activist investor Elliott Investment Management has built a sizeable stake in U.S. diagnostics supplier Bio-Rad Laboratories, and plans to push the company to boost its ...

Activist investor Elliott Investment Management has reportedly built a significant stake in Bio-Rad Laboratories Inc. (NYSE: ...

Elliott reportedly built a sizable Bio-Rad stake as the life-science tools supplier trades far below its late-2021 peak.

Ariel Investments, an investment management company, released its “Ariel Focus Fund” Q1 2026 Investor Letter. A copy of the letter can be downloaded here. The fund reported strong first-quarter ...

Elliott also has a stake in German lab-equipment supplier Sartorius, where Bio-Rad is also an investor.

The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low.